

PHILADELPHIA, Dec. 6 (UPI) -- Three U.S. health institutions say they've joined to evaluate a potential vaccine designed to prevent transmission of malaria from mosquitoes to humans.
The PATH Malaria Vaccine Initiative, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research will collaborate to conduct a Phase 1 clinical trial in healthy adults to assess the safety and effectiveness of the vaccine, a PATH release said Tuesday.
The Pfs25 vaccine aims to block transmission of malaria from mosquitoes to humans by preventing the malaria parasite from developing in the mosquito, researchers said.
"This is the first clinical trial supported by MVI to use a transmission-blocking approach," Ashley Birkett, director of research and development at MVI, said. "Eradication of malaria may be decades away, but we believe a successful TBV [transmission-blocking vaccine] -- used alongside safe and effective drugs, insecticides, bed nets and possibly a malaria vaccine that protects the individual against infection and disease -- would be essential to achieving that goal."
|
|
|
|
|
|
| Additional Health News Stories | |
MIAMI, May 27 (UPI) --
Tropical Storm Beryl neared hurricane strength ahead of its expected landfall Sunday night on the Southeast Coast of the United States, U.S. forecasters said.
|
TEL AVIV, Israel, May 27 (UPI) --
U.S. pop star Madonna requested producers of her Tel Aviv concert build her children a private pool on the grounds of the concert venue, sources told Haaretz.
|
ANCHORAGE, Alaska, May 27 (UPI) --
A black bear didn't go over a river but went to the woods after scampering through residential and industrial areas of Anchorage, Alaska, police said.
|
To avoid a meltdown in 2006, Ford Motor Co. mortgaged the farm putting up its assets – including its Blue Oval logo, and F-150 pickup and iconic Mustang trademarks – to secure $23.5 billion in credit.
|
| Stories | Photos | People | Comments |
View Caption